The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of Tranexamic Acid (TXA) intravenously, to Reduce Blood Loss in proximal femur surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures

NCT02580227

Hip Fractures Surgical Blood Loss

UNKNOWN PHASE4

Tranexamic Acid in Total Knee Replacement

NCT03656445

Osteo Arthritis Knee

COMPLETED NA

Use of Transexamic Acid in Hip Replacement

NCT02587845

Bleeding Transfusion Related Complication

UNKNOWN PHASE3

Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty

NCT02648295

Status Post Total Hip and Knee Arthroplasty

COMPLETED

Tranexamic Acid Dosing for Total Joint Arthroplasty

NCT02584725

Arthropathy of Hip Arthropathy of Knee

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Femur Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tranexamic Acid (TXA) treatment

Group Type EXPERIMENTAL

Tranexamic Acid (TXA) treatment

Intervention Type DRUG

Tranexamic Acid (TXA) treatment

control grup: without Tranexamic Acid (TXA) treatment.

Group Type EXPERIMENTAL

control grup: without Tranexamic Acid (TXA) treatment.

Intervention Type DRUG

control grup: without Tranexamic Acid (TXA) treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tranexamic Acid (TXA) treatment

Intervention Type DRUG

control grup: without Tranexamic Acid (TXA) treatment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 60, who came to the orthopedic department for proximal femur fracture surgery
* Sound judgment

Exclusion Criteria

* Known hypersensitivity to Tranexamic Acid or component solution provided
* Subarachnoid hemorrhage
* Acquired color blindness
* Myocardial infarction in 12 months before admission
* Unstable angina
* Known clotting disorders (Thromboembolic disease in the past, elongated PT and PTT, hypercoagulability),
* Kidney or liver failure
* Another situation prostate resection , pathologic fractures according to anamnesis or by imaging
* Oncology patients
* Patients on anticoagulation
* Patients undergoing vascular intervention ( coronary or peripheral ), which was inserted Supporter requires a Dual antiplatelet therapy

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No